Short Interest in UCB SA (OTCMKTS:UCBJY) Declines By 80.0%

UCB SA (OTCMKTS:UCBJY) was the recipient of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 200 shares, a drop of 80.0% from the November 30th total of 1,000 shares. Based on an average daily volume of 11,900 shares, the short-interest ratio is presently 0.0 days.

UCB Price Performance

OTCMKTS:UCBJY traded up $1.67 on Thursday, hitting $99.02. The stock had a trading volume of 4,786 shares, compared to its average volume of 17,454. The company has a fifty day moving average price of $95.86 and a two-hundred day moving average price of $88.13. UCB has a 1-year low of $42.54 and a 1-year high of $100.01. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.